In recent years, the narcissism drug market is anticipated to grow rapidly during the forecast period. The personality disorder narcissism is one of ten. People with these disorders think, feel, and act in ways that are harmful to them or others. In late adolescence and early adulthood, signs of personality problems frequently arise. Along with this, environmental, neurobiological and genetic are the various risk factors that will increase the prevalence rate of narcissism. Hence, the demand for narcissism drug is increased in the market.
Frequently Asked Questions
The market is segmented based on Segmentation, By Types (Classic, Vulnerable, Malignant, Others), Drugs Class (Antidepressants, Antianxiety, Antipsychotics, Others), Treatment (Medication, Psychotherapy), Route of Administration (Oral, Intravenous, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics, Others) – Industry Trends and Forecast to 2032.
.
The Global Narcissism Drug Market size was valued at USD 722.09 USD Million in 2024.
The Global Narcissism Drug Market is projected to grow at a CAGR of 7.89% during the forecast period of 2025 to 2032.
The major players operating in the market include Eli Lilly and Company , AstraZeneca , Novartis AG , Johnson & Johnson Private Limited , Teva Pharmaceutical Industries Ltd., Merck & Co.Inc. , Allergan , Medtronic , Bristol-Myers Squibb Company , Boehringer Ingelheim International GmbH. , Abbott , F. Hoffmann-La Roche Ltd. , AbbVie Inc. , Otsuka America PharmaceuticalInc. , Takeda Pharmaceutical Company Limited , Pfizer Inc. , GlaxoSmithKline plc , Sanofi , Merck KGaA , H. Lundbeck A/S .
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
